thyroid cancer Archives -

The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung

New era of genomic medicine begins as UK approves Lilly’s Retsevmo

https://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/

The FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting

Roche, Blueprint raise pressure on Lilly with new Gavreto approval

https://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/

Eisai’s drug finally funded after two year delay

NICE recommends funding for three thyroid cancer drugs

https://pharmaphorum.com/news/nice-recommends-funding-three-thyroid-cancer-drugs/

Thyroid cancer drugs are available in Scotland and Wales

NICE rejects Bayer and Eisai drugs in thyroid cancer

https://pharmaphorum.com/news/nhs-not-pay-thyroid-cancer-drugs-says-nice/

NICE unconvinced by survival data from Ipsen and Sanofi drugs

NICE wants to axe funding for two thyroid cancer drugs

https://pharmaphorum.com/news/nice-wants-axe-funding-two-thyroid-cancer-drugs/

Japanese firm has set money aside for emerging markets M&A.

Takeda preps for further acquisition

https://pharmaphorum.com/news/takeda-preps-acquisition/

Lenvima available in Scotland, not England.

Eisai bemoans UK’s north-south cancer divide

https://pharmaphorum.com/news/eisai-bemoans-north-south-thyroid-cancer-divide/

Thyroid cancer drug falls through gap in NHS funding

Eisai angry over thyroid cancer drug impasse in England

https://pharmaphorum.com/news/eisai-furious-england-blocks-cancer-drug-funding/

thyroid cancer